CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM067415
035-os BibID:(WoS)000392425200005 (Scopus)84991585385
Első szerző:Agca, R.
Cím:EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update / R. Agca, S. C. Heslinga, S. Rollefstad, M. Heslinga, I. B. McInnes, M. J. L. Peters, T. K. Kvien, M. Dougados, H. Radner, F. Atzeni, J. Primdahl, A. Södergren, S. Wallberg Jonsson, J. van Rompay, C. Zabalan, T. R. Pedersen, L. Jacobsson, K. de Vlam, M. A. Gonzalez-Gay, A. G. Semb, G. D. Kitas, Y. M. Smulders, Z. Szekanecz, N. Sattar, D. P. M. Symmons, M. T. Nurmohamed
Dátum:2017
ISSN:0003-4967
Megjegyzések:Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals Of The Rheumatic Diseases. - 76 : 1 (2017), p. 17-28. -
További szerzők:Heslinga, S. C. Rollefstad, S. Heslinga, M. McInnes, I. B. Peters, M. J. L. Kvien, Tore K. Dougados, Maxime Radner, H. Atzeni, F. Primdahl, Jette Södergren, A. Wallberg Jonsson, S. van Rompay, J. Zabalan, C. Pedersen, T. R. Jacobsson, L. de Vlam, K. Gonzalez-Gay, Miguel A. Semb, Anne Grete Kitas, George Smulders, Yvo M. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sattar, Naveed Symmons, D. P. M. Nurmohamed, Michael T.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM015844
Első szerző:Peters, M. J. L.
Cím:EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis / Peters, M. J. L., Symmons, D. P. M., McCarey, D., Dijkmans, B. A. C., Nicola, P., Kvien, T. K., McInnes, I. B., Haentzschel, H., Gonzalez-Gay, M. A., Provan, S., Semb, A., Sidiropoulos, P., Kitas, G., Smulders, Y. M., Soubrier, M., Szekanecz, Z., Sattar, N., Nurmohamed, M. T.
Dátum:2010
ISSN:1468-2060 (Electronic)
Megjegyzések:To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). METHODS: A multidisciplinary expert committee was convened as a task force of the EULAR Standing Committee for Clinical Affairs (ESCCA), comprising 18 members including rheumatologists, cardiologists, internists and epidemiologists, representing nine European countries. Problem areas and related keywords for systematic literature research were identified. A systematic literature research was performed using MedLine, Embase and the Cochrane library through to May 2008. Based on this literature review and in accordance with the EULAR's "standardised operating procedures", the multidisciplinary steering committee formulated evidence-based and expert opinion-based recommendations for CV risk screening and management in patients with inflammatory arthritis. RESULTS: Annual CV risk assessment using national guidelines is recommended for all patients with RA and should be considered for all patients with AS and PsA. Any CV risk factors identified should be managed according to local guidelines. If no local guidelines are available, CV risk management should be carried out according to the SCORE function. In addition to appropriate CV risk management, aggressive suppression of the inflammatory process is recommended to further lower the CV risk. CONCLUSIONS: Ten recommendations were made for CV risk management in patients with RA, AS and PsA. The strength of the recommendations differed between RA on the one hand, and AS and PsA, on the other, as evidence for an increased CV risk is most compelling for RA.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Antihypertensive Agents/therapeutic use
Arthritis, Psoriatic/*complications
Arthritis, Rheumatoid/*complications
Cardiovascular Diseases/*etiology/*prevention & control
Cholesterol/blood
Drug Administration Schedule
Evidence-Based Medicine/methods
Female
Glucocorticoids/administration & dosage
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
Male
Risk Management/methods
Spondylitis, Ankylosing/*complications
Megjelenés:Annals of the Rheumatic Diseases. - 69 : 2 (2010), p. 325-331. -
További szerzők:Symmons, D. P. M. McCarey, D. Dijkmans, B. A. C. Nicola, P. Kvien, Tore K. McInnes, I. B. Haentzschel, H. Gonzalez-Gay, Miguel A. Provan, S. Semb, A. Sidiropoulos, P. Kitas, George Smulders, Yvo M. Soubrier, M. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sattar, Naveed Nurmohamed, Michael T.
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
elektronikus változat
Borító:
Rekordok letöltése1